{
    "1641405063405903872": {
        "attachments": {
            "media_keys": [
                "3_1641405061463941121"
            ]
        },
        "author_id": "5383942",
        "created_at": "2023-03-30T11:40:37.000Z",
        "edit_history_tweet_ids": [
            "1641405063405903872"
        ],
        "entities": {
            "annotations": [
                {
                    "end": 135,
                    "normalized_text": "GSK",
                    "probability": 0.6308,
                    "start": 133,
                    "type": "Organization"
                },
                {
                    "end": 216,
                    "normalized_text": "AMR",
                    "probability": 0.2898,
                    "start": 214,
                    "type": "Other"
                }
            ],
            "hashtags": [
                {
                    "end": 5,
                    "start": 0,
                    "tag": "News"
                },
                {
                    "end": 20,
                    "start": 10,
                    "tag": "Investors"
                },
                {
                    "end": 31,
                    "start": 25,
                    "tag": "Media"
                }
            ],
            "mentions": [
                {
                    "end": 104,
                    "id": "855489284576620546",
                    "start": 95,
                    "username": "scynexis"
                }
            ],
            "urls": [
                {
                    "display_url": "gsk.to/3zh3XY2",
                    "end": 258,
                    "expanded_url": "https://gsk.to/3zh3XY2",
                    "start": 235,
                    "status": 200,
                    "unwound_url": "https://www.gsk.com/en-gb/home/?linkId=100000197008506",
                    "url": "https://t.co/4sW2jyQMA0"
                },
                {
                    "display_url": "pic.twitter.com/IpGZwqsxLt",
                    "end": 282,
                    "expanded_url": "https://twitter.com/GSK/status/1641405063405903872/photo/1",
                    "media_key": "3_1641405061463941121",
                    "start": 259,
                    "url": "https://t.co/IpGZwqsxLt"
                }
            ]
        },
        "id": "1641405063405903872",
        "lang": "en",
        "public_metrics": {
            "bookmark_count": 0,
            "impression_count": 6055,
            "like_count": 22,
            "quote_count": 2,
            "reply_count": 1,
            "retweet_count": 2
        },
        "text": "#News for #Investors and #Media \n\nToday we\u2019ve entered into an exclusive licence agreement with @scynexis. This agreement complements GSK\u2019s infectious diseases portfolio and builds on our commitment to get ahead of AMR.\n\nFind out more: https://t.co/4sW2jyQMA0 https://t.co/IpGZwqsxLt"
    }
}